Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.28%
0%
-9.28%
6 Months
-4.44%
0%
-4.44%
1 Year
-12.24%
0%
-12.24%
2 Years
-29.51%
0%
-29.51%
3 Years
-63.25%
0%
-63.25%
4 Years
-78.92%
0%
-78.92%
5 Years
-89.56%
0%
-89.56%
Ixico Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.82%
EBIT Growth (5y)
-206.81%
EBIT to Interest (avg)
-0.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.71
Tax Ratio
7.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.37%
ROE (avg)
4.19%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.00
EV to EBIT
-3.23
EV to EBITDA
-4.00
EV to Capital Employed
1.00
EV to Sales
1.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-30.87%
ROE (Latest)
-12.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Sep'23
Sep'23
Sep'22
Change(%)
Net Sales
6.70
8.60
-22.09%
Operating Profit (PBDIT) excl Other Income
-1.10
0.70
-257.14%
Interest
0.00
0.00
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-1.20
1.00
-220.00%
Operating Profit Margin (Excl OI)
-259.70%
12.80%
-27.25%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2023 is -22.09% vs -6.52% in Sep 2022
Consolidated Net Profit
YoY Growth in year ended Sep 2023 is -220.00% vs -33.33% in Sep 2022
About Ixico Plc 
Ixico Plc
Miscellaneous
IXICO plc is a brain health company. The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Parkinson's disease, behavioral health and adolescent mental health. It is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker. Assessa is a decision-support tool for healthcare professionals looking to diagnose dementia and detect the underlying causes. mehealth is an online software for clinicians at the point-of-care to support decision making and improve the monitoring and treatment of patients. MyBrainBook is a digital platform to improve the quality of life and service delivery for people living with dementia and their supporters. TrialTracker is a Web-based system that allows users to track their imaging-based research study or clinical trial in real time. It is also collaborating with partners to develop companion digital health products.
Company Coordinates 
Company Details
4th Fl, Griffin Court, 15 Long Lane , LONDON None : EC1A 9PN
Registrar Details






